Skip to main content
Fujian Cosunter Pharmaceutical Co., Ltd. logo

Fujian Cosunter Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300436 ISIN · CNE100001YZ0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,835 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300436

About Fujian Cosunter Pharmaceutical Co., Ltd.

https://www.cosunter.com

Fujian Cosunter Pharmaceutical Co., Ltd. specializes in the research, development, production, and commercialization of pharmaceutical products. The company maintains a strong focus on antiviral therapies, particularly for the treatment of chronic Hepatitis B, with a product portfolio featuring Entecavir, Tenofovir Disoproxil Fumarate, and Adefovir Dipivoxil. Its therapeutic reach extends to cardiovascular, respiratory, and digestive system medications. The organization operates integrated manufacturing platforms and research centers dedicated to the innovation of small molecule drugs and high-end generic formulations. By leveraging advanced chemical synthesis and formulation technologies, the company delivers a diverse range of therapeutic solutions aimed at addressing unmet medical needs and improving patient health outcomes.

Recent filings

Filing Released Lang Actions
关于2025年年度股东会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 Annual General Meeting (AGM) resolutions, detailing meeting attendance and vote counts for each proposed agenda item. It publishes the official voting results rather than providing the full annual report or AGM materials. This matches the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-20 Chinese
国浩律师（上海）事务所关于福建广生堂药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm regarding the convening, procedural compliance, attendance, voting procedures, and results of the company’s 2025 Annual General Meeting. It does not itself present financial statements or functioning as the AGM materials but serves as a legal certification/opinion. By the certification rule, a standalone legal opinion or attestation letter is classified as a general Regulatory Filing (RNS), not as the actual AGM materials or voting declaration. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-20 Chinese
国联民生证券承销保荐有限公司关于福建广生堂药业股份有限公司2025年度向特定对象发行A股股票之发行保荐书
Share Issue/Capital Change Classification · 85% confidence The document is a detailed “发行保荐书” (sponsor’s letter) prepared by the underwriting/sponsoring institution for Fujian Guangshengtang Pharmaceutical Co., Ltd.’s 2025 directed issuance of A-shares to specific investors. It includes comprehensive information on the share issuance structure, pricing, regulatory compliance, due diligence, financial data, and the sponsor’s recommendation. This is not merely an announcement but the actual regulatory filing and substantive document for a new share issuance. Therefore, it fits the “Share Issue/Capital Change” category.
2026-05-11 Chinese
关于福建广生堂药业股份有限公司申请向特定对象发行股票的第二轮审核问询函的回复
Regulatory Filings Classification · 85% confidence The document is a formal response letter to the Shenzhen Stock Exchange’s second‐round review inquiry regarding Fujian Guangshengtang’s proposed non‐public share issuance. It is part of the regulatory filing process for a specific object issuance of A‐shares rather than a financial report (10‐K/IR), earnings announcement (ER), or other specific category. There is no dedicated “prospectus Q&A” category, so the appropriate classification is Regulatory Filings (RNS).
2026-05-11 Chinese
国浩律师（上海）事务所关于福建广生堂药业股份有限公司2025年度向特定对象发行A股股票之补充法律意见书（八）
Regulatory Filings Classification · 84% confidence The document is a lengthy “Supplementary Legal Opinion” (第八号补充法律意见书) issued by Grandall Law Firm in connection with Fujian Guangshengtang Pharmaceutical’s 2025 private placement of A-shares. It is a legal due-diligence opinion mandated by regulatory bodies (CSRC, Shenzhen Stock Exchange) for a share issuance, rather than an earnings release, financial report, management discussion, or proxy statement. It does not contain standalone financial statements or constitute the actual share issuance announcement itself. As it is a specialized compliance/legal opinion that does not fit other precise categories, it should be classified under the fallback “Regulatory Filings” category (RNS).
2026-05-11 Chinese
2025年度向特定对象发行A股股票募集说明书
Regulatory Filings
2026-05-11 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.